However, the drug is not approved for the treatment of squamous cell lung cancer because of the potential adverse events including pneumorrhagia and pulmonary embolism.[4] In addition, as an anti-VEGFR2 inhibitor, ramucirumab was also attempted for the salvage therapy in patients with NSCLC.[14] However, the results of subgroup analysis revealed that regimen of ramucirumab combined with docetaxel did not significantly prolong survival time compared to docetaxel alone in patients with squamous cell lung cancer (9.5 versus 8.2 months, HR 0.88, 95%CI: 0.69 to 1.13). Here, KDR is linked to pulmonary embolism.